The increased global prevalence of infectious diseases is a primary driver for the global market for ceftriaxone sodium (API).
Covid-19 Impact & Market Status
COVID-19 had an influence on many manufacturing and service-providing businesses in 2020-2021, resulting in job losses, supply chain disruptions, and transportation limitations. However, the imbalance between demand and supply, as well as its impact on pricing, is only projected to last a few months until the pandemic ends. As a result, the demand for ceftriaxone sodium has risen. Infected patients also experienced significant body discomfort and muscular agony, which aided the growth of the heating pad business during the epidemic. In addition, heating pad manufacturers debuted new and improved heating pad models. As a result, the heating pad sector flourished tremendously during the COVID-19 pandemic, despite the fact that other industries lost greatly.
This report presents opportunities that exist to successfully approach and fulfill growing market demands along with clear understanding of the major investment segments, its underlying risks, and future opportunities. The report studies the dynamics of the market such as market drivers, growth constraints, current trends, and existing opportunities. The report provides global and national forecasts of the market from 2022 to 2029. Organization can benefit emerging market opportunities highlighted in the report. Most importantly, the report studies how the market hit by the pandemic and strategies implemented by the market players to recover from the loss.
The market players will understand the near-term and distant threats to their business operations and investments and strategies on how to protect the company against future risks. The market players gain insight on latest trends that could strengthen or disrupt business activities in the global Ceftriaxone Sodium market. The report covers end-user industries, market trends, and perspectives of key players. The Global Ceftriaxone Sodium market report analyzes the key geographic regions and territories, major countries for the market in listed regions. The report provides updated profiles of leading companies in all the regions and countries in the market and summary of regulatory environment in individual country and trade policies.
North America Retained The Topmost Position
North America retained the topmost position in global ceftriaxone sodium market owing to factors such as better technological improvements and economic expansion, North America is likely to take a significant share of the worldwide ceftriaxone sodium (API) market. Due to a rise in investment by various firms in building up manufacturing units for the production of generic pharmaceuticals in general, as well as a cheap labour workforce, South Asia and East Asia are predicted to be the fastest expanding markets in the global market for ceftriaxone sodium (API).
The global Ceftriaxone Sodium market was worth USD 271.1 million in 2021 and is predicted to reach USD 226.2 million by 2029, increasing at a CAGR of -2.7 percent between 2022 and 2029.
Another important driver for the expansion of the API industry in general will be the expiration of patentability of blockbuster pharmaceuticals in the coming years, allowing generic manufacturers to manufacture generic versions of these drugs.
Growing geriatric population, which has a weakened immune system, would contribute to the growth of the global ceftriaxone sodium (API) market, as they are the most susceptible to infection.
The global prevalence of hospital-acquired infections is increasing is driving the global ceftriaxone sodium market. People are predicted to become more susceptible to infections as the number of surgeries increases, which would boost the global market for ceftriaxone sodium (API).
Ceftriaxone Sodium (API) is a third-generation cephalosporin that is sometimes included in anti-infection medications of following surgery. Middle ear infections, urinary tract infections, gonorrhoea, endocarditis, bone and joint infections, meningitis, skin infections, pneumonia, intra-abdominal infections, and pelvic inflammatory disease are all treated with Ceftriaxone Sodium (API).
Following these deadlines, the huge pharma behemoths outsource the manufacturing process, allowing them to focus on their core strengths of medication discovery. Collaborations like these are expected to propel the ceftriaxone sodium (API) industry ahead. People are becoming more susceptible to infections as a result of changing lifestyles and life choices such as smoking, which will push the global market for ceftriaxone sodium to develop (API).
Furthermore, the global prevalence of hospital-acquired infections is increasing, which will cause the international market for ceftriaxone sodium to increase (API). People are predicted to become more susceptible to infections as the number of surgeries increases, which would boost the global market for ceftriaxone sodium (API).
Building production capacity costs a lot of money, which could stifle the API industry's overall growth, as well as the ceftriaxone sodium (API) market's. Also, lack of qualified labour in emerging market production units could be a major barrier contributing stifled growth of the global ceftriaxone sodium's growth (API) market.
Furthermore, the growing geriatric population, which has a weakened immune system, would contribute to the growth of the global ceftriaxone sodium (API) market, as they are the most susceptible to infection.
The increased global prevalence of infectious diseases is a primary driver for the global market for ceftriaxone sodium (API). Another important driver for the expansion of the API industry in general will be the expiration of patentability of blockbuster pharmaceuticals in the coming years, allowing generic manufacturers to manufacture generic versions of these drugs.
.png "Global Ceftriaxone Sodium Market 2019-2029 (USD Million)")
The major market players in global Ceftriaxone Sodium Market are Youcare Pharmaceutical Group, Fujian Fukang Pharmaceutical, China Union Chempharma, Sinopharm Sandwich, Livzon Pharmaceutical, Qilu Antibiotics Pharmaceutical, Lupin Pharmaceuticals, North China Pharmaceutical, Shanghai Pharmaceutical, United Laboratories, and Shandong Luoxin
Major Developments in Ceftriaxone Sodium Market: A Snapshot
- Recently, Cambrex acquired Avista Pharma Solutions to develop the ceftriaxone sodium (API) sector. The acquisition will provide early stage API and final dosage form development and testing capabilities to its global contract development and manufacturing network.
Ceftriaxone Sodium Market Scope
| Metrics | Details |
| Base Year | 2023 |
| Historic Data | 2018-2022 |
| Forecast Period | 2024-2029 |
| Study Period | 2018-2029 |
| Forecast Unit | Value (USD) |
| Revenue forecast in 2029 | USD 226.2 million |
| Growth Rate | CAGR of 2.7 % during 2021-2029 |
| Segment Covered | Type,, Application, Regions |
| Regions Covered | North America, Europe, Asia Pacific, Middle East and Africa, South America |
| Key Players Profiled | Youcare Pharmaceutical Group, Fujian Fukang Pharmaceutical, China Union Chempharma, Sinopharm Sandwich, Livzon Pharmaceutical, Qilu Antibiotics Pharmaceutical, Lupin Pharmaceuticals, North China Pharmaceutical, Shanghai Pharmaceutical, United Laboratories, and Shandong Luoxin |
Key Segments of Global Ceftriaxone Sodium Market
Type Overview, 2022-2029 (USD Million)
- ChP
- USP
- EP
Application Overview, 2022-2029 (USD Million)
- Single Injection
- Compound Injection
Regional Overview, 2022-2029 (USD Million)
North America
- U.S
- Canada
Europe
- Germany
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
South America
- Mexico
- Brazil
- Rest of South America
Middle East and South Africa
Frequently Asked Questions (FAQ) :
The market value of Ceftriaxone Sodium market in 2029 was USD 226.2 million.
The Ceftriaxone Sodium market is growing at a CAGR of 2.7% over the forecast period.
The application of the Ceftriaxone Sodium market single injection, compound injection.
North America dominated the market for Ceftriaxone Sodium market and accounted for the largest revenue share.
The top companies that hold the market share in Ceftriaxone Sodium market are Youcare Pharmaceutical Group, Fujian Fukang Pharmaceutical, China Union Chempharma, Sinopharm Sandwich, Livzon Pharmaceutical, Qilu Antibiotics Pharmaceutical, Lupin Pharmaceuticals, North China Pharmaceutical, Shanghai Pharmaceutical, United Laboratories, and Shandong Luoxin.